James W. Sharpe
Keine laufenden Positionen mehr
Profil
James W.
Sharpe was President and Chief Executive Officer of Astralis Ltd.
He received an MBA from the University of Rochester and a BS degree from Union College.
Ehemalige bekannte Positionen von James W. Sharpe
| Unternehmen | Position | Ende |
|---|---|---|
Astralis Ltd.
 Astralis Ltd. BiotechnologyHealth Technology Astralis Ltd. research and develop drugs for the treatment of immune system disorders and skin diseases. The company's initial product is Psoraxine, a protein extract used for the treatment of the skin disease psoriasis. Psoraxine is a synthesized immuno-therapeutic agent, presented in liquid form and is packed in 0.5 mg ampules for intra-muscular injection. The company's second product is for the treatment of leishmaniasis. The company was founded on June 30, 2001 and is headquartered in Fairfield, NJ. | Präsident | 25.01.2006 |
Ausbildung von James W. Sharpe
| Rochester Christian University | Masters Business Admin |
| Union College (New York) | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Astralis Ltd.
Astralis Ltd. BiotechnologyHealth Technology Astralis Ltd. research and develop drugs for the treatment of immune system disorders and skin diseases. The company's initial product is Psoraxine, a protein extract used for the treatment of the skin disease psoriasis. Psoraxine is a synthesized immuno-therapeutic agent, presented in liquid form and is packed in 0.5 mg ampules for intra-muscular injection. The company's second product is for the treatment of leishmaniasis. The company was founded on June 30, 2001 and is headquartered in Fairfield, NJ. | Health Technology |
